Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/12/2025

Diagnostic Tests and Monitoring Strategies for MGUS

Initial Diagnostic Workup

  • The diagnosis of Monoclonal Gammopathy of Undetermined Significance (MGUS) requires serum monoclonal protein <3 g/dl, clonal bone marrow plasma cells <10%, and absence of end-organ damage (CRAB criteria: hypercalcemia, renal insufficiency, anemia, and bone lesions) 1
  • Serum protein electrophoresis (SPEP) is used to detect and quantify M-protein 1
  • Serum immunofixation electrophoresis (SIFE) is used to characterize heavy and light chains 1
  • Quantitative immunoglobulin levels (IgG, IgA, and IgM) are essential for diagnosis 1
  • Serum free light chain (FLC) assay with kappa/lambda ratio is a crucial test 1
  • Complete blood count is used to rule out anemia 2, 1
  • Serum calcium and creatinine are used to assess for end-organ damage 1
  • Qualitative test for urine protein, followed by urine protein electrophoresis and immunofixation if positive, is recommended 1

Risk Stratification

  • Low-risk MGUS is defined as serum M-protein <15 g/L, IgG type, and normal FLC ratio 1
  • Intermediate/high-risk MGUS is defined as serum M-protein >15 g/L, and/or IgA or IgM protein type, and/or abnormal FLC ratio 1

Additional Testing Based on Risk

  • Baseline bone marrow examination or skeletal radiography is not routinely indicated for low-risk MGUS 1
  • Bone marrow aspirate and biopsy at baseline are recommended to rule out underlying plasma cell malignancy in intermediate/high-risk MGUS 1
  • Conventional cytogenetics and fluorescence in situ hybridization (FISH) on bone marrow sample are recommended for intermediate/high-risk MGUS 1
  • Plasma cell labeling index and search for circulating plasma cells using flow cytometry are recommended if available 1
  • Computed tomography scan of the abdomen is recommended to check for asymptomatic retroperitoneal lymph nodes in IgM MGUS 1

Monitoring Recommendations

  • Repeat SPEP is recommended in 6 months after diagnosis for low-risk MGUS 1
  • Follow-up every 2-3 years or when symptoms suggestive of plasma cell malignancy arise is recommended for low-risk MGUS 1
  • Follow-up with SPEP and complete blood count is recommended in 6 months for intermediate/high-risk MGUS 1
  • Annual follow-up is recommended for life for intermediate/high-risk MGUS 1

Important Clinical Considerations

  • MGUS must be differentiated from smoldering multiple myeloma (SMM) and symptomatic multiple myeloma 1
  • SMM has a higher risk of progression (10% per year over first 5 years) compared to MGUS (1% per year) 2
  • Bone marrow examination is always required if a patient with presumed MGUS has unexplained anemia, renal insufficiency, hypercalcemia, bone lesions, or suspicion of AL amyloidosis 1
  • Patients should be instructed to contact their physician if there is any change in their clinical condition 1
  • Failing to differentiate MGUS from SMM or MM, which have different management approaches, is a common pitfall to avoid 1
  • Discontinuing follow-up after a period of stability is not recommended as progression risk continues lifelong 1
  • Missing the diagnosis by not performing immunofixation when SPEP is negative or equivocal is a common pitfall to avoid 1
  • Initiating treatment for MGUS outside of clinical trials is not recommended 1